mRNA-1273 boost after BNT162b2 vaccination generates comparable SARS-CoV-2-specific functional responses in naïve and COVID-19-recovered individuals
IntroductionCOVID-19 vaccines based on mRNA have represented a revolution in the biomedical research field. The initial two-dose vaccination schedule generates potent humoral and cellular responses, with a massive protective effect against severe COVID-19 and death. Months after this vaccination, le...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-04-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1136029/full |
| _version_ | 1797843247478865920 |
|---|---|
| author | Roberto Lozano-Rodríguez Roberto Lozano-Rodríguez José Avendaño-Ortíz José Avendaño-Ortíz Verónica Terrón Verónica Terrón Karla Montalbán-Hernández Karla Montalbán-Hernández José Casalvilla-Dueñas José Casalvilla-Dueñas Marta Bergón-Gutiérrez Marta Bergón-Gutiérrez Pablo Mata-Martínez Pablo Mata-Martínez Alejandro Martín-Quirós Miguel Ángel García-Garrido Álvaro del Balzo-Castillo Álvaro del Balzo-Castillo María Peinado Laura Gómez Irene Llorente-Fernández Gema Martín-Miguel Carmen Herrero-Benito Lissette López-Morejón Carmen Vela-Olmo Carolina Cubillos-Zapata Carolina Cubillos-Zapata Carolina Cubillos-Zapata Eduardo López-Collazo Eduardo López-Collazo Eduardo López-Collazo Carlos del Fresno Carlos del Fresno |
| author_facet | Roberto Lozano-Rodríguez Roberto Lozano-Rodríguez José Avendaño-Ortíz José Avendaño-Ortíz Verónica Terrón Verónica Terrón Karla Montalbán-Hernández Karla Montalbán-Hernández José Casalvilla-Dueñas José Casalvilla-Dueñas Marta Bergón-Gutiérrez Marta Bergón-Gutiérrez Pablo Mata-Martínez Pablo Mata-Martínez Alejandro Martín-Quirós Miguel Ángel García-Garrido Álvaro del Balzo-Castillo Álvaro del Balzo-Castillo María Peinado Laura Gómez Irene Llorente-Fernández Gema Martín-Miguel Carmen Herrero-Benito Lissette López-Morejón Carmen Vela-Olmo Carolina Cubillos-Zapata Carolina Cubillos-Zapata Carolina Cubillos-Zapata Eduardo López-Collazo Eduardo López-Collazo Eduardo López-Collazo Carlos del Fresno Carlos del Fresno |
| author_sort | Roberto Lozano-Rodríguez |
| collection | DOAJ |
| description | IntroductionCOVID-19 vaccines based on mRNA have represented a revolution in the biomedical research field. The initial two-dose vaccination schedule generates potent humoral and cellular responses, with a massive protective effect against severe COVID-19 and death. Months after this vaccination, levels of antibodies against SARS-CoV-2 waned, and this promoted the recommendation of a third vaccination dose.MethodsWe have performed an integral and longitudinal study of the immunological responses triggered by the booster mRNA-1273 vaccination, in a cohort of health workers previously vaccinated with two doses of the BNT162b2 vaccine at University Hospital La Paz located in Madrid, Spain. Circulating humoral responses and SARS-CoV-2-specific cellular reactions, after ex vivo restimulation of both T and B cells (cytokines production, proliferation, class switching), have been analyzed. Importantly, all along these studies, the analyses have been performed comparing naïve and subjects recovered from COVID-19, addressing the influence of a previous infection by SARS-CoV-2. Furthermore, as the injection of the third vaccination dose was contemporary to the rise of the Omicron BA.1 variant of concern, T- and B-cell-mediated cellular responses have been comparatively analyzed in response to this variant.ResultsAll these analyses indicated that differential responses to vaccination due to a previous SARS-CoV-2 infection were balanced following the boost. The increase in circulating humoral responses due to this booster dropped after 6 months, whereas T-cell-mediated responses were more stable along the time. Finally, all the analyzed immunological features were dampened in response to the Omicron variant of concern, particularly late after the booster vaccination.ConclusionThis work represents a follow-up longitudinal study for almost 1.5 years, analyzing in an integral manner the immunological responses triggered by the prime-boost mRNA-based vaccination schedule against COVID-19. |
| first_indexed | 2024-04-09T17:02:04Z |
| format | Article |
| id | doaj.art-7381bc1db10a43eebad5271b06226978 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-09T17:02:04Z |
| publishDate | 2023-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-7381bc1db10a43eebad5271b062269782023-04-21T04:36:17ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-04-011410.3389/fimmu.2023.11360291136029mRNA-1273 boost after BNT162b2 vaccination generates comparable SARS-CoV-2-specific functional responses in naïve and COVID-19-recovered individualsRoberto Lozano-Rodríguez0Roberto Lozano-Rodríguez1José Avendaño-Ortíz2José Avendaño-Ortíz3Verónica Terrón4Verónica Terrón5Karla Montalbán-Hernández6Karla Montalbán-Hernández7José Casalvilla-Dueñas8José Casalvilla-Dueñas9Marta Bergón-Gutiérrez10Marta Bergón-Gutiérrez11Pablo Mata-Martínez12Pablo Mata-Martínez13Alejandro Martín-Quirós14Miguel Ángel García-Garrido15Álvaro del Balzo-Castillo16Álvaro del Balzo-Castillo17María Peinado18Laura Gómez19Irene Llorente-Fernández20Gema Martín-Miguel21Carmen Herrero-Benito22Lissette López-Morejón23Carmen Vela-Olmo24Carolina Cubillos-Zapata25Carolina Cubillos-Zapata26Carolina Cubillos-Zapata27Eduardo López-Collazo28Eduardo López-Collazo29Eduardo López-Collazo30Carlos del Fresno31Carlos del Fresno32The Innate Immune Response Group, Hospital la Paz Institute for Health Research (IdiPAZ), La Paz University Hospital, Madrid, SpainTumor Immunology Laboratory, Hospital la Paz Institute for Health Research (IdiPAZ), La Paz University Hospital, Madrid, SpainThe Innate Immune Response Group, Hospital la Paz Institute for Health Research (IdiPAZ), La Paz University Hospital, Madrid, SpainTumor Immunology Laboratory, Hospital la Paz Institute for Health Research (IdiPAZ), La Paz University Hospital, Madrid, SpainThe Innate Immune Response Group, Hospital la Paz Institute for Health Research (IdiPAZ), La Paz University Hospital, Madrid, SpainTumor Immunology Laboratory, Hospital la Paz Institute for Health Research (IdiPAZ), La Paz University Hospital, Madrid, SpainThe Innate Immune Response Group, Hospital la Paz Institute for Health Research (IdiPAZ), La Paz University Hospital, Madrid, SpainTumor Immunology Laboratory, Hospital la Paz Institute for Health Research (IdiPAZ), La Paz University Hospital, Madrid, SpainThe Innate Immune Response Group, Hospital la Paz Institute for Health Research (IdiPAZ), La Paz University Hospital, Madrid, SpainTumor Immunology Laboratory, Hospital la Paz Institute for Health Research (IdiPAZ), La Paz University Hospital, Madrid, SpainThe Innate Immune Response Group, Hospital la Paz Institute for Health Research (IdiPAZ), La Paz University Hospital, Madrid, SpainImmunomodulation Laboratory, Hospital la Paz Institute for Health Research (IdiPAZ), La Paz University Hospital, Madrid, SpainThe Innate Immune Response Group, Hospital la Paz Institute for Health Research (IdiPAZ), La Paz University Hospital, Madrid, SpainImmunomodulation Laboratory, Hospital la Paz Institute for Health Research (IdiPAZ), La Paz University Hospital, Madrid, SpainEmergency Department and Emergent Pathology Research Group, Hospital la Paz Institute for Health Research (IdiPAZ), La Paz University Hospital, Madrid, SpainEmergency Department and Emergent Pathology Research Group, Hospital la Paz Institute for Health Research (IdiPAZ), La Paz University Hospital, Madrid, SpainThe Innate Immune Response Group, Hospital la Paz Institute for Health Research (IdiPAZ), La Paz University Hospital, Madrid, SpainEmergency Department and Emergent Pathology Research Group, Hospital la Paz Institute for Health Research (IdiPAZ), La Paz University Hospital, Madrid, SpainEmergency Department and Emergent Pathology Research Group, Hospital la Paz Institute for Health Research (IdiPAZ), La Paz University Hospital, Madrid, SpainEmergency Department and Emergent Pathology Research Group, Hospital la Paz Institute for Health Research (IdiPAZ), La Paz University Hospital, Madrid, SpainIntensive Care Unit, Infanta Cristina University Hospital, Parla, Madrid, SpainPediatric Intensive Care Unit, 12 de Octubre University Hospital, Madrid, SpainEmergency Department and Emergent Pathology Research Group, Hospital la Paz Institute for Health Research (IdiPAZ), La Paz University Hospital, Madrid, SpainEurofins-Ingenasa, Madrid, SpainEurofins-Ingenasa, Madrid, SpainThe Innate Immune Response Group, Hospital la Paz Institute for Health Research (IdiPAZ), La Paz University Hospital, Madrid, SpainTumor Immunology Laboratory, Hospital la Paz Institute for Health Research (IdiPAZ), La Paz University Hospital, Madrid, SpainCentro de Investigación Biomédica en Red (CIBER) of Respiratory Diseases (CIBERES), Madrid, SpainThe Innate Immune Response Group, Hospital la Paz Institute for Health Research (IdiPAZ), La Paz University Hospital, Madrid, SpainTumor Immunology Laboratory, Hospital la Paz Institute for Health Research (IdiPAZ), La Paz University Hospital, Madrid, SpainCentro de Investigación Biomédica en Red (CIBER) of Respiratory Diseases (CIBERES), Madrid, SpainThe Innate Immune Response Group, Hospital la Paz Institute for Health Research (IdiPAZ), La Paz University Hospital, Madrid, SpainImmunomodulation Laboratory, Hospital la Paz Institute for Health Research (IdiPAZ), La Paz University Hospital, Madrid, SpainIntroductionCOVID-19 vaccines based on mRNA have represented a revolution in the biomedical research field. The initial two-dose vaccination schedule generates potent humoral and cellular responses, with a massive protective effect against severe COVID-19 and death. Months after this vaccination, levels of antibodies against SARS-CoV-2 waned, and this promoted the recommendation of a third vaccination dose.MethodsWe have performed an integral and longitudinal study of the immunological responses triggered by the booster mRNA-1273 vaccination, in a cohort of health workers previously vaccinated with two doses of the BNT162b2 vaccine at University Hospital La Paz located in Madrid, Spain. Circulating humoral responses and SARS-CoV-2-specific cellular reactions, after ex vivo restimulation of both T and B cells (cytokines production, proliferation, class switching), have been analyzed. Importantly, all along these studies, the analyses have been performed comparing naïve and subjects recovered from COVID-19, addressing the influence of a previous infection by SARS-CoV-2. Furthermore, as the injection of the third vaccination dose was contemporary to the rise of the Omicron BA.1 variant of concern, T- and B-cell-mediated cellular responses have been comparatively analyzed in response to this variant.ResultsAll these analyses indicated that differential responses to vaccination due to a previous SARS-CoV-2 infection were balanced following the boost. The increase in circulating humoral responses due to this booster dropped after 6 months, whereas T-cell-mediated responses were more stable along the time. Finally, all the analyzed immunological features were dampened in response to the Omicron variant of concern, particularly late after the booster vaccination.ConclusionThis work represents a follow-up longitudinal study for almost 1.5 years, analyzing in an integral manner the immunological responses triggered by the prime-boost mRNA-based vaccination schedule against COVID-19.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1136029/fullmRNA vaccineCOVID-19 boosterSARS-CoV-2-specificnaïverecovered from COVID-19 |
| spellingShingle | Roberto Lozano-Rodríguez Roberto Lozano-Rodríguez José Avendaño-Ortíz José Avendaño-Ortíz Verónica Terrón Verónica Terrón Karla Montalbán-Hernández Karla Montalbán-Hernández José Casalvilla-Dueñas José Casalvilla-Dueñas Marta Bergón-Gutiérrez Marta Bergón-Gutiérrez Pablo Mata-Martínez Pablo Mata-Martínez Alejandro Martín-Quirós Miguel Ángel García-Garrido Álvaro del Balzo-Castillo Álvaro del Balzo-Castillo María Peinado Laura Gómez Irene Llorente-Fernández Gema Martín-Miguel Carmen Herrero-Benito Lissette López-Morejón Carmen Vela-Olmo Carolina Cubillos-Zapata Carolina Cubillos-Zapata Carolina Cubillos-Zapata Eduardo López-Collazo Eduardo López-Collazo Eduardo López-Collazo Carlos del Fresno Carlos del Fresno mRNA-1273 boost after BNT162b2 vaccination generates comparable SARS-CoV-2-specific functional responses in naïve and COVID-19-recovered individuals Frontiers in Immunology mRNA vaccine COVID-19 booster SARS-CoV-2-specific naïve recovered from COVID-19 |
| title | mRNA-1273 boost after BNT162b2 vaccination generates comparable SARS-CoV-2-specific functional responses in naïve and COVID-19-recovered individuals |
| title_full | mRNA-1273 boost after BNT162b2 vaccination generates comparable SARS-CoV-2-specific functional responses in naïve and COVID-19-recovered individuals |
| title_fullStr | mRNA-1273 boost after BNT162b2 vaccination generates comparable SARS-CoV-2-specific functional responses in naïve and COVID-19-recovered individuals |
| title_full_unstemmed | mRNA-1273 boost after BNT162b2 vaccination generates comparable SARS-CoV-2-specific functional responses in naïve and COVID-19-recovered individuals |
| title_short | mRNA-1273 boost after BNT162b2 vaccination generates comparable SARS-CoV-2-specific functional responses in naïve and COVID-19-recovered individuals |
| title_sort | mrna 1273 boost after bnt162b2 vaccination generates comparable sars cov 2 specific functional responses in naive and covid 19 recovered individuals |
| topic | mRNA vaccine COVID-19 booster SARS-CoV-2-specific naïve recovered from COVID-19 |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1136029/full |
| work_keys_str_mv | AT robertolozanorodriguez mrna1273boostafterbnt162b2vaccinationgeneratescomparablesarscov2specificfunctionalresponsesinnaiveandcovid19recoveredindividuals AT robertolozanorodriguez mrna1273boostafterbnt162b2vaccinationgeneratescomparablesarscov2specificfunctionalresponsesinnaiveandcovid19recoveredindividuals AT joseavendanoortiz mrna1273boostafterbnt162b2vaccinationgeneratescomparablesarscov2specificfunctionalresponsesinnaiveandcovid19recoveredindividuals AT joseavendanoortiz mrna1273boostafterbnt162b2vaccinationgeneratescomparablesarscov2specificfunctionalresponsesinnaiveandcovid19recoveredindividuals AT veronicaterron mrna1273boostafterbnt162b2vaccinationgeneratescomparablesarscov2specificfunctionalresponsesinnaiveandcovid19recoveredindividuals AT veronicaterron mrna1273boostafterbnt162b2vaccinationgeneratescomparablesarscov2specificfunctionalresponsesinnaiveandcovid19recoveredindividuals AT karlamontalbanhernandez mrna1273boostafterbnt162b2vaccinationgeneratescomparablesarscov2specificfunctionalresponsesinnaiveandcovid19recoveredindividuals AT karlamontalbanhernandez mrna1273boostafterbnt162b2vaccinationgeneratescomparablesarscov2specificfunctionalresponsesinnaiveandcovid19recoveredindividuals AT josecasalvilladuenas mrna1273boostafterbnt162b2vaccinationgeneratescomparablesarscov2specificfunctionalresponsesinnaiveandcovid19recoveredindividuals AT josecasalvilladuenas mrna1273boostafterbnt162b2vaccinationgeneratescomparablesarscov2specificfunctionalresponsesinnaiveandcovid19recoveredindividuals AT martabergongutierrez mrna1273boostafterbnt162b2vaccinationgeneratescomparablesarscov2specificfunctionalresponsesinnaiveandcovid19recoveredindividuals AT martabergongutierrez mrna1273boostafterbnt162b2vaccinationgeneratescomparablesarscov2specificfunctionalresponsesinnaiveandcovid19recoveredindividuals AT pablomatamartinez mrna1273boostafterbnt162b2vaccinationgeneratescomparablesarscov2specificfunctionalresponsesinnaiveandcovid19recoveredindividuals AT pablomatamartinez mrna1273boostafterbnt162b2vaccinationgeneratescomparablesarscov2specificfunctionalresponsesinnaiveandcovid19recoveredindividuals AT alejandromartinquiros mrna1273boostafterbnt162b2vaccinationgeneratescomparablesarscov2specificfunctionalresponsesinnaiveandcovid19recoveredindividuals AT miguelangelgarciagarrido mrna1273boostafterbnt162b2vaccinationgeneratescomparablesarscov2specificfunctionalresponsesinnaiveandcovid19recoveredindividuals AT alvarodelbalzocastillo mrna1273boostafterbnt162b2vaccinationgeneratescomparablesarscov2specificfunctionalresponsesinnaiveandcovid19recoveredindividuals AT alvarodelbalzocastillo mrna1273boostafterbnt162b2vaccinationgeneratescomparablesarscov2specificfunctionalresponsesinnaiveandcovid19recoveredindividuals AT mariapeinado mrna1273boostafterbnt162b2vaccinationgeneratescomparablesarscov2specificfunctionalresponsesinnaiveandcovid19recoveredindividuals AT lauragomez mrna1273boostafterbnt162b2vaccinationgeneratescomparablesarscov2specificfunctionalresponsesinnaiveandcovid19recoveredindividuals AT irenellorentefernandez mrna1273boostafterbnt162b2vaccinationgeneratescomparablesarscov2specificfunctionalresponsesinnaiveandcovid19recoveredindividuals AT gemamartinmiguel mrna1273boostafterbnt162b2vaccinationgeneratescomparablesarscov2specificfunctionalresponsesinnaiveandcovid19recoveredindividuals AT carmenherrerobenito mrna1273boostafterbnt162b2vaccinationgeneratescomparablesarscov2specificfunctionalresponsesinnaiveandcovid19recoveredindividuals AT lissettelopezmorejon mrna1273boostafterbnt162b2vaccinationgeneratescomparablesarscov2specificfunctionalresponsesinnaiveandcovid19recoveredindividuals AT carmenvelaolmo mrna1273boostafterbnt162b2vaccinationgeneratescomparablesarscov2specificfunctionalresponsesinnaiveandcovid19recoveredindividuals AT carolinacubilloszapata mrna1273boostafterbnt162b2vaccinationgeneratescomparablesarscov2specificfunctionalresponsesinnaiveandcovid19recoveredindividuals AT carolinacubilloszapata mrna1273boostafterbnt162b2vaccinationgeneratescomparablesarscov2specificfunctionalresponsesinnaiveandcovid19recoveredindividuals AT carolinacubilloszapata mrna1273boostafterbnt162b2vaccinationgeneratescomparablesarscov2specificfunctionalresponsesinnaiveandcovid19recoveredindividuals AT eduardolopezcollazo mrna1273boostafterbnt162b2vaccinationgeneratescomparablesarscov2specificfunctionalresponsesinnaiveandcovid19recoveredindividuals AT eduardolopezcollazo mrna1273boostafterbnt162b2vaccinationgeneratescomparablesarscov2specificfunctionalresponsesinnaiveandcovid19recoveredindividuals AT eduardolopezcollazo mrna1273boostafterbnt162b2vaccinationgeneratescomparablesarscov2specificfunctionalresponsesinnaiveandcovid19recoveredindividuals AT carlosdelfresno mrna1273boostafterbnt162b2vaccinationgeneratescomparablesarscov2specificfunctionalresponsesinnaiveandcovid19recoveredindividuals AT carlosdelfresno mrna1273boostafterbnt162b2vaccinationgeneratescomparablesarscov2specificfunctionalresponsesinnaiveandcovid19recoveredindividuals |